[go: up one dir, main page]

MX2022010568A - Métodos y composiciones que usan nanoportadores sintéticos que comprenden inmunosupresor. - Google Patents

Métodos y composiciones que usan nanoportadores sintéticos que comprenden inmunosupresor.

Info

Publication number
MX2022010568A
MX2022010568A MX2022010568A MX2022010568A MX2022010568A MX 2022010568 A MX2022010568 A MX 2022010568A MX 2022010568 A MX2022010568 A MX 2022010568A MX 2022010568 A MX2022010568 A MX 2022010568A MX 2022010568 A MX2022010568 A MX 2022010568A
Authority
MX
Mexico
Prior art keywords
immunosuppressant
methods
compositions
synthetic nanocarriers
nanocarriers
Prior art date
Application number
MX2022010568A
Other languages
English (en)
Inventor
Petr Ilyinskii
Takashi Kei Kishimoto
Original Assignee
Selecta Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2020/028132 external-priority patent/WO2021211100A1/en
Application filed by Selecta Biosciences Inc filed Critical Selecta Biosciences Inc
Publication of MX2022010568A publication Critical patent/MX2022010568A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporcionan en la presente métodos y composiciones relacionados con nanoportadores sintéticos que comprenden un inmunosupresor que pueden usarse, por ejemplo, para inducir autofagia y/o promover un fenotipo tolerógeno.
MX2022010568A 2020-02-26 2021-02-26 Métodos y composiciones que usan nanoportadores sintéticos que comprenden inmunosupresor. MX2022010568A (es)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US202062981595P 2020-02-26 2020-02-26
US202062981584P 2020-02-26 2020-02-26
US202062981602P 2020-02-26 2020-02-26
US202062981612P 2020-02-26 2020-02-26
US202062981594P 2020-02-26 2020-02-26
US202062981606P 2020-02-26 2020-02-26
US202062981586P 2020-02-26 2020-02-26
US202062981589P 2020-02-26 2020-02-26
PCT/US2020/028132 WO2021211100A1 (en) 2020-04-14 2020-04-14 Methods and compositions for inducing autophagy
PCT/US2021/019927 WO2021174013A1 (en) 2020-02-26 2021-02-26 Methods and compositions using synthetic nanocarriers comprising immunosuppressant

Publications (1)

Publication Number Publication Date
MX2022010568A true MX2022010568A (es) 2022-11-30

Family

ID=74947602

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022010568A MX2022010568A (es) 2020-02-26 2021-02-26 Métodos y composiciones que usan nanoportadores sintéticos que comprenden inmunosupresor.

Country Status (10)

Country Link
US (1) US20210290601A1 (es)
EP (1) EP4110334A1 (es)
JP (1) JP2023515202A (es)
KR (1) KR20220146559A (es)
CN (1) CN115379839A (es)
AU (1) AU2021225955A1 (es)
CA (1) CA3173734A1 (es)
IL (1) IL295868A (es)
MX (1) MX2022010568A (es)
WO (1) WO2021174013A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117205331A (zh) 2011-04-29 2023-12-12 西莱克塔生物科技公司 用于降低抗体应答的致耐受性合成纳米载体
US10668053B2 (en) 2013-05-03 2020-06-02 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers to reduce or prevent anaphylaxis in response to a non-allergenic antigen
HUE072005T2 (hu) 2017-03-11 2025-10-28 Cartesian Therapeutics Inc Gyulladásgátlókkal és immunszupresszánst tartalmazó szintetikus nanohordozókkal történõ kombinált kezeléssel összefüggõ eljárások és készítmények
CA3180166A1 (en) * 2020-04-14 2021-10-21 Selecta Biosciences, Inc. Methods and compositions for inducing autophagy
ES2986744A1 (es) * 2023-04-13 2024-11-12 Servicio Andaluz De Salud Rapamicina y estatinas como protectores frente daño hepático
CN117860782B (zh) * 2024-03-11 2024-05-28 中国康复科学所(中国残联残疾预防与控制研究中心) 双阴性t细胞在制备治疗脊髓损伤的药物中的用途

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946929A (en) 1983-03-22 1990-08-07 Massachusetts Institute Of Technology Bioerodible articles useful as implants and prostheses having predictable degradation rates
US4638045A (en) 1985-02-19 1987-01-20 Massachusetts Institute Of Technology Non-peptide polyamino acid bioerodible polymers
US4806621A (en) 1986-01-21 1989-02-21 Massachusetts Institute Of Technology Biocompatible, bioerodible, hydrophobic, implantable polyimino carbonate article
CA1340581C (en) 1986-11-20 1999-06-08 Joseph P. Vacanti Chimeric neomorphogenesis of organs by controlled cellular implantation using artificial matrices
US5804178A (en) 1986-11-20 1998-09-08 Massachusetts Institute Of Technology Implantation of cell-matrix structure adjacent mesentery, omentum or peritoneum tissue
US5736372A (en) 1986-11-20 1998-04-07 Massachusetts Institute Of Technology Biodegradable synthetic polymeric fibrous matrix containing chondrocyte for in vivo production of a cartilaginous structure
US5019379A (en) 1987-07-31 1991-05-28 Massachusetts Institute Of Technology Unsaturated polyanhydrides
US5010167A (en) 1989-03-31 1991-04-23 Massachusetts Institute Of Technology Poly(amide-and imide-co-anhydride) for biological application
US5399665A (en) 1992-11-05 1995-03-21 Massachusetts Institute Of Technology Biodegradable polymers for cell transplantation
US5843452A (en) * 1992-11-09 1998-12-01 Pharmagenesis, Inc. Immunotherapy composition and method
US5512600A (en) 1993-01-15 1996-04-30 Massachusetts Institute Of Technology Preparation of bonded fiber structures for cell implantation
US5514378A (en) 1993-02-01 1996-05-07 Massachusetts Institute Of Technology Biocompatible polymer membranes and methods of preparation of three dimensional membrane structures
US5565215A (en) 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US6007845A (en) 1994-07-22 1999-12-28 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
US5716404A (en) 1994-12-16 1998-02-10 Massachusetts Institute Of Technology Breast tissue engineering
US6123727A (en) 1995-05-01 2000-09-26 Massachusetts Institute Of Technology Tissue engineered tendons and ligaments
US6095148A (en) 1995-11-03 2000-08-01 Children's Medical Center Corporation Neuronal stimulation using electrically conducting polymers
US5902599A (en) 1996-02-20 1999-05-11 Massachusetts Institute Of Technology Biodegradable polymer networks for use in orthopedic and dental applications
US6258823B1 (en) 1996-07-12 2001-07-10 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
US5837752A (en) 1997-07-17 1998-11-17 Massachusetts Institute Of Technology Semi-interpenetrating polymer networks
US6506577B1 (en) 1998-03-19 2003-01-14 The Regents Of The University Of California Synthesis and crosslinking of catechol containing copolypeptides
US6686446B2 (en) 1998-03-19 2004-02-03 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
US6632922B1 (en) 1998-03-19 2003-10-14 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
MXPA02008361A (es) 2000-02-28 2004-05-17 Genesegues Inc Sistema y metodo de encapsulacion de nanocapsulas.
GB0025414D0 (en) 2000-10-16 2000-11-29 Consejo Superior Investigacion Nanoparticles
WO2003020797A1 (en) 2001-08-30 2003-03-13 The Regents Of The University Of California Transition metal initiators for controlled poly (beta-peptide) synthesis from beta-lactam monomers
KR101281775B1 (ko) 2003-12-19 2013-07-15 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 소프트 또는 임프린트 리소그래피를 이용하여 분리된마이크로- 및 나노- 구조를 제작하는 방법
EP1768692B8 (en) 2004-07-01 2015-06-17 Yale University Targeted and high density drug loaded polymeric materials
JP2010523656A (ja) 2007-04-12 2010-07-15 エモリー・ユニバーシティ ミセルおよび粒子を用いた、活性物質の送達のための新規の戦略
EP3424525A1 (en) 2007-10-12 2019-01-09 Massachusetts Institute Of Technology Vaccine nanotechnology
CN101676291B (zh) 2008-09-18 2012-05-09 上海海和药物研究开发有限公司 一类雷帕霉素碳酸酯类似物、其药物组合物及其制备方法和用途
CN117205331A (zh) * 2011-04-29 2023-12-12 西莱克塔生物科技公司 用于降低抗体应答的致耐受性合成纳米载体
US10668053B2 (en) * 2013-05-03 2020-06-02 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers to reduce or prevent anaphylaxis in response to a non-allergenic antigen
US20150359865A1 (en) * 2014-06-17 2015-12-17 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers for t-cell-mediated autoimmune disease
EA201790977A1 (ru) 2014-11-05 2017-10-31 Селекта Байосайенсиз, Инк. Способы и композиции, относящиеся к применению поверхностно-активных веществ с низким показателем гидрофильно-липофильного баланса (hlb) при получении синтетических наноносителей, включающих рапалог
WO2017139212A1 (en) * 2016-02-08 2017-08-17 Cyta Therapeutics, Inc. Particle delivery of rapamycin to the liver
US20190142974A1 (en) * 2017-10-13 2019-05-16 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
WO2021081062A1 (en) * 2019-10-21 2021-04-29 Selecta Biosciences, Inc. Methods and compositions for treating liver diseases and disorders
CA3180166A1 (en) * 2020-04-14 2021-10-21 Selecta Biosciences, Inc. Methods and compositions for inducing autophagy
US20230263906A1 (en) * 2022-01-10 2023-08-24 Selecta Biosciences, Inc. High affinity il-2 receptor agonists and synthetic nanocarrier dose sparing
WO2023183568A1 (en) * 2022-03-25 2023-09-28 Selecta Biosciences, Inc. Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists and anti-igm agents
WO2023196566A1 (en) * 2022-04-08 2023-10-12 Selecta Biosciences, Inc. High affinity il-2 receptor agonists and immunosuppressants to enhance immune tolerance

Also Published As

Publication number Publication date
US20210290601A1 (en) 2021-09-23
CN115379839A (zh) 2022-11-22
EP4110334A1 (en) 2023-01-04
WO2021174013A1 (en) 2021-09-02
IL295868A (en) 2022-10-01
CA3173734A1 (en) 2021-09-02
KR20220146559A (ko) 2022-11-01
AU2021225955A1 (en) 2022-09-22
JP2023515202A (ja) 2023-04-12

Similar Documents

Publication Publication Date Title
MX2022010568A (es) Métodos y composiciones que usan nanoportadores sintéticos que comprenden inmunosupresor.
PH12022550469A1 (en) Kras g12d inhibitors
MX2021000285A (es) Composiciones que comprenden cepas bacterianas.
WO2017156513A8 (en) Formulations and doses of pegylated uricase
MX2021002180A (es) Composiciones de inhibidores del receptor de quimiocina c-x-c tipo 4 (cxcr4) y metodos de preparacion y uso.
PH12019500208A1 (en) Spiro-lactam nmda receptor modulators and methods of using same
CY1125211T1 (el) Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη
MY209471A (en) Interleukin-2 agents and uses thereof
MY209474A (en) Il-2 conjugates and methods of use to treat autoimmune diseases
PH12018502438A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MY201811A (en) Method of reducing neutropenia
PH12020551637A1 (en) Additives for protein formulations to improve thermal stability
MX2022004983A (es) Composiciones de profarmaco y metodos de tratamiento.
PH12019500202A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12019500207A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12019500206A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
GEP20247585B (en) Furoindazole derivatives
MX2020011817A (es) Metodos para tratar el linfoma.
SA522431538B1 (ar) طُرق وتركيبات لعلاج تساقط الشعر
MY209035A (en) Tricyclic compounds and their use
ZA202109829B (en) Super-oxide dismutase soluble fiber compositions
MX2022005506A (es) Formulaciones y dosis de uricasa pegilada.
MX2020013389A (es) Composiciones de terlipresina y usos de las mismas.
MX2021004396A (es) Metodos y composiciones para el tratamiento de la mucositis oral.
MX2021012577A (es) Metodo para tratar el sindrome de abstinencia neonatal de opioides.